Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 19.
doi: 10.1111/jdv.20698. Online ahead of print.

SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata

Ziad Reguiai  1 , Leila Asfour  2 , Delphine Staumont-Sallé  3 , Ángela Hermosa-Gelbard  4 , Andrea Sechi  5 , Dalia Wajsbrot  6 , Rahmat Ishowo-Adejumo  7 , Deborah Woodworth  7 , Alexandre Lejeune  8
Affiliations

SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata

Ziad Reguiai et al. J Eur Acad Dermatol Venereol. .
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double‐blind, multicentre, phase 2b‐3 trial. Lancet. 2023;401(10387):1518–1529. https://doi.org/10.1016/s0140‐6736(23)00222‐2
    1. Piliang M, Soung J, King B, Shapiro J, Rudnicka L, Farrant P, et al. Efficacy and safety of the oral JAK3/TEC family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase 2b/3 and long‐term phase 3 clinical studies in alopecia areata. Br J Dermatol. 2025;192(2):215–227. https://doi.org/10.1093/bjd/ljae365
    1. King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, et al. Integrated safety analysis of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program. Am J Clin Dermatol. 2024;25(2):299–314. https://doi.org/10.1007/s40257‐024‐00846‐3

Grants and funding

LinkOut - more resources